Septerna (NASDAQ:SEPN) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Septerna (NASDAQ:SEPN) in a research report report published on Tuesday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $38.00 target price on the stock.

Several other brokerages have also recently issued reports on SEPN. Wells Fargo & Company initiated coverage on shares of Septerna in a report on Tuesday. They set an “overweight” rating and a $43.00 target price for the company. TD Cowen initiated coverage on Septerna in a report on Tuesday. They issued a “buy” rating for the company. Finally, Cantor Fitzgerald assumed coverage on Septerna in a research note on Tuesday. They issued an “overweight” rating and a $50.00 target price on the stock.

Septerna Price Performance

SEPN opened at $24.20 on Tuesday. Septerna has a 12-month low of $18.62 and a 12-month high of $26.34.

Insider Buying and Selling at Septerna

In other Septerna news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the transaction, the insider now directly owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.